A refractory anti-NMDA receptor encephalitis successfully treated by bilateral ovariectomy and intrathecal injection of methotrexate and dexamethasone: A case report

Dongmei Wang
Southern Medical University Nanfang Hospital

Yongming Wu
Southern Medical University Nanfang Hospital

Zhong Ji
Southern Medical University Nanfang Hospital

Shengnan Wang
Southern Medical University Nanfang Hospital

Yunqi Xu
Southern Medical University Nanfang Hospital

Kaibin Huang
Southern Medical University Nanfang Hospital

Yu Peng
Southern Medical University Nanfang Hospital

Hui Zheng
Southern Medical University Nanfang Hospital

Honghao Wang
Southern Medical University Nanfang Hospital

Xiaomei Zhang
Southern Medical University Nanfang Hospital

Suyue Pan pansuyue82@126.com
Southern Medical University Nanfang Hospital
Corresponding Author

DOI:
Intrathecal injection of MTX and DXM may be beneficial for patients with anti-NMDA receptor encephalitis
Abstract

Background: Anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis is an autoimmune-mediated disease, which is predominant in young female patients with ovarian teratomas. With proper immunotherapy, most of the patients achieve good prognosis. Nevertheless, some patients may be refractory to first and second-line immunotherapy, thus new treatments are required to help these patients. Case presentation: We present a case of anti-NMDA receptor encephalitis with ovary teratoma. After the prompt removal of the teratoma and strong immunotherapy including intravenous methylprednisolone pulse (IVMP), intravenous immunoglobulin (IVIG), plasmapheresis, immunoadsorption, intravenous cyclophosphamide, and rituximab, the patient’s neurologic status did not improve. Bilateral ovariectomy was then conducted and intrathecal injection of methotrexate (MTX) and dexamethasone (DXM) was given. The patient’s neurological symptoms improved dramatically and she achieved a good prognosis after 23 months. Conclusions: For refractory cases of anti-NMDA receptor encephalitis, intrathecal injection of MTX and DXM may be beneficial. More research is required to elucidate the mechanisms of intrathecal treatment.

Background

Anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis has recently been reported as paraneoplastic limbic encephalitis, which mainly affects young females with ovary teratomas [1]. Clinical therapy, including first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis), second-line immunotherapy (rituximab, cyclophosphamide), and tumor removal is recommended for the treatment of this condition. With proper therapy, most of the patients achieve good prognosis (modified Rankin Scale, mRS < 2) within 24-month follow up [2]. Nevertheless, about 19% patients
may have a poor prognosis following the first and second line treatment.

Ovarian teratomas were reported to be associated with the disease in 58% of the cases [3]. The teratomas contain neuronal cells that result in immunologic sensitization against the NMDA receptors and even small teratomas containing nervous tissue may result in severe complications secondary to anti-NMDA receptor encephalitis [4]. The longest clinical duration of coma in anti-NMDA receptor encephalitis has not yet been reported. Herein, we present a case of anti-NMDA receptor encephalitis with right side ovarian teratoma. The patient was refractory to the first and second line therapy. Bilateral ovariectomy was conducted and intrathecal injection of methotrexate (MTX) and dexamethasone (DXM) was initiated. The patient finally recovered consciousness and a good prognosis at 17 months and 23 months from the onset of the disease, respectively.

Case Presentation

A 27-year old female was transferred to our department following three seizure episodes and loss of consciousness that occurred on Nov 4, 2016 and lasted for one day. She was admitted at a local psychiatric department for acute psychosis that lasted for 3 days during which she spoke few words, was restless and unwilling to eat. A week before her symptoms appeared, she had cold-like symptoms with a runny nose and low-grade fever between 37-38°C. Her past medical history was not remarkable.

On admission, physical examination revealed that her vital signs were stable and neurological examination based on Glasgow coma scale showed that she had a score of 6 (E1V1M4). Laboratory results and electroencephalogram (EEG) were not remarkable. Cranial MRI with contrast showed mild signal changes in the bilateral hippocampus and left temporal cortex, and local meningeal congestion. Anti-NMDA receptor antibodies were detected in the serum and cerebrospinal fluid (CSF) (1:1000 and 1:100, respectively). Abdominal ultrasound screening showed a weak liquid echo of the right ovary, and
teratoma was highly suspected. Tumor removal was initiated after the diagnosis was made on Nov 5, 2016, and the pathology confirmed the diagnosis of teratoma with nerve tissues inside.

The patient was comatose with persistent facial involuntary movement including lip peristalsis and eyebrow winking, which were treated with a large dosage of anesthetic agents.

After the diagnosis of anti-NMDA receptor encephalitis was made, the first line therapy including intravenous methylprednisolone pulse (IVMP), intravenous immunoglobulin (IVIG), plasmapheresis and immunoabsorption was conducted. However, the patient was refractory to all the treatment. Her neurological status did not improve and the titers of anti-NMDA receptor antibodies in both serum and CSF were persistently high (Table 1). Considering the poor reaction to treatment, the second line therapy that included rituximab and intravenous cyclophosphamide was initiated. The patient did not react to this treatment.

Since patient manifested the high titer of antibodies, it made us consider non-visible teratomas of the ovaries. After obtaining the informed consent from the family members, bilateral ovariectomy was conducted on Oct 26, 2017 and the pathology revealed inflammation, while no teratoma was seen.

Immunosuppressant including mycophenolate mofetil (MMF) 0.75g bid was initiated after the failure of the first and second line therapy. Intrathecal MTX 10 mg and DXM 10 mg were given once a week for 5 weeks and the titer of the antibody of CSF gradually decreased (Table 1) and during the follow-up, the titer decreased to 1:10 on April 20, 2018. After the therapy, the patient awoke after 17 months. With 6-month physical therapy, she achieved a good prognosis with the mRS score of 1. During the follow-up, an X-ray examination of the patients' shoulders showed diffused muscular ossification (Figure
Discussion And Conclusion

A large cohort study enrolling 577 patients have found that in most patients with anti-NMDA receptor encephalitis, respond to immunotherapy and second-line immunotherapy is usually effective when first-line treatments fail. In some patients in this cohort, the recovery took up to 18 months [2]. The patient in our study had a poor response to both the first and second line therapy, which made it a refractory case.

The comorbidity of teratoma and anti-NMDA receptor encephalitis has been widely reported. The incidence varies from 6% to 38% with lower incidence in younger patients [2, 5]. Delayed teratoma development and image invisible teratoma have been previously reported [1, 6]. Zainab et al. have described a case of a patient who received bilateral oophorectomy though multiple imaging investigations showed no evidence of teratomas. Ovarian histology confirmed the diagnosis of teratoma with nerve tissues [1]. In our case, at the onset of the disease, the ultrasound revealed a teratoma of the right ovary and tumor removal was conducted within a week of the disease. The unresponsive effect of the treatment made us consider the possibility of non-visible teratomas. Based on the clinical suspicion of tiny teratomas, the patient underwent bilateral ovariectomy. However, the pathology did not show any evidence of teratomas.

Intrathecal injection of MTX and DXM has shown to be beneficial to treat neuropsychiatric systemic lupus erythematosus (NPSLE) patients, particularly those patients who were refractory to traditional therapy or those who had contraindications for IVMP and intravenous cyclophosphamide [7]. The therapy has been widely used in treating NPSLE[8, 9]. A study that evaluated the effect of methylprednisolone combined with MTX and DXM in NPSLE patients and its effect on anti-NMDA receptor subtype NR2a/2b antibody level has reported that after the treatment, positive rates of autoantibodies and anti-NR2
antibody in both NPSLE and non-NPSLE group were significantly decreased, while the negative conversion rate was as high as 61.5%[10]. Based on the encouraging effect of intrathecal injection of MTX and DXM in NPSLE, we tried this therapy in our patient. The neurologic status of our patient improved dramatically after the intrathecal therapy. MTX is a potent immunosuppressive agent, which cannot penetrate the blood-brain barrier. Intrathecal administration can increase the local concentration and thus enhance the immunosuppressive effect [8]. Nonetheless, intrathecal injection of MTX should be used with caution in anti-NMDA receptor encephalitis. A case report of a young female patient with methotrexate neurotoxicity was worth our consideration. EEG of the young female leukemia patient with a high dosage of intrathecal MTX showed delta brush [11], which has been reported in about 30.3% patients with anti-NMDA receptor encephalitis [12]. NMDA receptor is involved in the pathogenesis of MTX neurotoxicity. MTX interferes with potentially neurotoxic amino acid and neurotransmitter pathways causing accumulation of homocysteine and its metabolites with strong excitatory effect on NMDA receptors [13]. These findings seem paradoxical. We hypothesize that MTX has some effect on NMDA receptors and appropriate dosage may be beneficial for anti-NMDA receptor encephalitis. Further research is warranted to elucidate the underlying mechanisms in intrathecal MTX for patients with anti-NMDA receptor encephalitis.

Another interesting point in this case is that the patient developed severe and diffused muscle ossification. This phenomenon is heterotopic ossification (HO) and is consistent with our experience [14]. Very severe neurologic symptoms, long-term intensive care, muscular spasticity, and mechanical ventilation were probably the cause of HO development in the patient.

Anti-NMDA receptor encephalitis is a newly recognized auto-immune disease. In most patients, favorable prognosis is achieved with the first and second-line immune therapy.
In some rare cases, in which patients poorly react to strong first and second-line treatment, intrathecal MTX with DEM may be beneficial.

Abbreviations:

anti-NMDA: Anti-N-methyl-d-aspartate; CSF: cerebrospinal fluid; DXM: dexamethasone; EEG: electroencephalogram; HO: heterotopic ossification; IVMP: intravenous methylprednisolone pulse; IVIG: intravenous immunoglobin; MMF: mycophenolate mofetil; mRS: modified Rankin Scale; MTX: methotrexate; NPSLE: neuropsychiatric systemic lupus erythematosus.

Declarations

Ethics approval and consent to participate

Institutional review board/ethics committee approval was obtained from the Institutional Review Board of the Nanfang Hospital, Southern Medical University.

Consent to publish

Written informed consents were obtained from the patient and her parents for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Competing interests

The authors declared no conflicts of interest with respect to the research, authorship, funding, and/or publication of this article.

Funding

This study was supported by the National Key R&D Program of China (2017YFC1307500) and the National Natural Science Foundation of China (No. 81871030). SP was funded by the two funds and he was responsible for the concept and design of the study. Also, SP
revised the manuscript.

**Authors' Contributions**

DW, YW, ZJ, SW and SP are responsible for concepts and design. YX, KH, YP, HZ and HW are responsible for taking care of the patient. DW and XZ are responsible for data collecting. All authors contributed intellectually. All authors acquired, analyzed, and interpreted the data. The manuscript was prepared by DW and SP. All authors reviewed and made critical revisions to the manuscript.

**Acknowledgements**

We thank the patient and her family members for their generosity and cooperation.

**References**

1. Abdul-Rahman ZM, Panegyres PK, Roeck M, Hawkins D, Bharath J, Grolman P, Neppe C, Palmer D: Anti-N-methyl-D-aspartate receptor encephalitis with an imaging-invisible ovarian teratoma: a case report. *J Med Case Rep* 2016, 10(1):296.

2. Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E et al: Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. *Lancet Neurol* 2013, 12(2):157-165.

3. Azizyan A, Albrektson JR, Maya MM, Pressman BD, Moser F: Anti-NMDA encephalitis: an uncommon, autoimmune mediated form of encephalitis. *J Radiol Case Rep* 2014, 8(8):1-6.

4. Acien P, Acien M, Ruiz-Macia E, Martin-Estefania C: Ovarian teratoma-associated anti-NMDAR encephalitis: a systematic review of reported cases. *Orphanet J Rare Dis* 2014, 9:157.

5. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R: Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. *Lancet Neurol* 2011, 10(1):63-74.
6. Omata T, Kodama K, Watanabe Y, Iida Y, Furusawa Y, Takashima A, Takahashi Y, Sakuma H, Tanaka K, Fujii K et al: Ovarian teratoma development after anti-NMDA receptor encephalitis treatment. Brain Dev 2017, 39(5):448-451.

7. Valesini G, Priori R, Francia A, Balestrieri G, Tincani A, Airo P, Cattaneo R, Zambruni A, Troianello B, Chofflon M et al: Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol 1994, 16(2-3):313-321.

8. Zhou HQ, Zhang FC, Tian XP, Leng XM, Lu JJ, Zhao Y, Tang FL, Zhang X, Zeng XF, Zhang ZL et al: Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients. Lupus 2008, 17(2):93-99.

9. Zhou HQ, Leng XM, Zhang FC: [Neuropsychiatric manifestations in systemic lupus erythematosus and the treatment of intrathecal methotrexate plus dexamethasone]. Zhonghua Yi Xue Za Zhi 2006, 86(11):771-774.

10. Wang J, Zhao Y, Zhang J, Lei H, Zhu G, Fu B: Impact analysis of autoantibody level and NR2 antibody level in neuropsychiatric SLE treated by methylprednisolone combined with MTX and DXM intrathecal injection. Cell Biochem Biophys 2014, 70(2):1005-1009.

11. Schmidt LS, Kjaer TW, Schmiegelow K, Born AP: EEG with extreme delta brush in young female with methotrexate neurotoxicity supports NMDA receptor involvement. Eur J Paediatr Neurol 2017, 21(5):795-797.

12. Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D: Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012, 79(11):1094-1100.

13. Vezmar S, Becker A, Bode U, Jaehde U: Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003, 49(1-2):92-104.

14. Wang D, Wang S, Huang X, Wang Q: Heterotopic ossification following anti-NMDA
receptor encephalitis: a case report. *BMC Neurol* 2016, 16(1):232.

**Table**

Table 1 Clinical treatment and serum and CSF antibody titers of the patient.

| Date           | Immunotherapy                        | Serum anti-NMDA receptor titer | CSF anti-NMDA receptor titer | Infections                                      |
|---------------|--------------------------------------|-------------------------------|-----------------------------|------------------------------------------------|
| Nov 5, 2016   | Plasma Exchange for 5 days            | 1:1000                        | 1:100                       |                                                |
| Nov 6, 2016   | IVMP with 0.5g/d for 5 days and tapered to oral MP 40mg | 1:1000                        | 1:100                       |                                                 |
| Nov 10, 2016  | IVIG with 20g for 5 days              | 1:1000                        | 1:100                       |                                                 |
| Nov 21, 2016  | IVIG with 20g for 5 days              | 1:1000                        | 1:100                       |                                                 |
| Dec 1, 2016   | Plasma Exchange for 5 days            | 1:1000                        | 1:100                       |                                                 |
| Dec 15, 2016  | Oral MP 40mg                          | 1:1000                        | 1:100                       | Septicemia with *Staphylococcus goats*         |
| Dec 22, 2016  | IV CTX 0.4g                           | 1:1000                        | 1:100                       |                                                 |
| Dec 29, 2016  | IV CTX 0.6g                           | 1:1000                        | 1:100                       |                                                 |
| Jan 11, 2017  | IVIG with 20g for 5 days              | 1:1000                        | 1:100                       |                                                 |
| Jan 13, 2017  | IVMP with 0.5g/d for 5 days and tapered to oral MP 40mg | 1:1000                        | 1:100                       |                                                 |
| Feb 17, 2017  | Immunoadsorption for 5 days           | 1:1000                        | 1:100                       |                                                 |
| Mar 7, 2017   | Rituximab 100mg Qw for 4 weeks        | 1:300                         | 1:100                       | Septicemia with *klebsiella pneumoniae*        |
| Apr 28, 2017  | Plasma Exchange for 5 days            | 1:300                         | 1:100                       |                                                 |
| May 14, 2017  | Plasma Exchange for 5 days            | 1:300                         | 1:100                       |                                                 |
| Dec 12, 2017  | Mycophenolate mofetil (MMF) 0.75g bid | 1:300                         | 1:100                       |                                                 |
| Dec 26, 2017  | IVIG with 20g for 5 days              | 1:300                         | 1:100                       |                                                 |
| Dec 26, 2017  | IVMP with 0.5g/d for 3 days and tapered to oral MP 40mg | 1:300                         | 1:100                       |                                                 |
| Jan 16, 2018  | Intrathecal therapy with DXM and MTX for 5 times (Once per week) | 1:300                         | 1:32                        |                                                 |

DXM: dexamethasone; IVMP: intravenous methylprednisolone pulse; IVIG: intravenous immunoglobulin; MMF: mycophenolate mofetil; MP: methylprednisolone; MTX: methotrexate.

**Figures**
Figure 1

Chest-X-ray examinations of the patient. No significant ossification was observed at the beginning of the disease (Nov 15, 2016) (a). During the disease period (Aug 26, 2018), diffused ossifications were observed in the right scapula and upper humerus (black arrows) (b). With proper physical therapy, the ossifications were decreased (black arrow, Sept 11, 2018) (c).

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

CAREchecklist-English.pdf